CRBP Valuation

Corbus Pharmaceuticals Holdings Inc

Add to Watchlist

Advanced Chart

11.560

+0.06(0.522%)1D

Overview
Forecast
Valuation
Earnings

CRBP Relative Valuation

CRBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRBP is overvalued; if below, it's undervalued.

Historical Valuation

Corbus Pharmaceuticals Holdings Inc (CRBP) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -5.48. The fair price of Corbus Pharmaceuticals Holdings Inc (CRBP) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 11.56 USD , Corbus Pharmaceuticals Holdings Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：11.56

Fair

Undervalued

-1.90

Trailing

Forward

-0.31

EV/EBITDA

Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current EV/EBITDA of -0.31. The 5-year average EV/EBITDA is -0.90. The thresholds are as follows: Strongly Undervalued below -5.97, Undervalued between -5.97 and -3.43, Fairly Valued between 1.64 and -3.43, Overvalued between 1.64 and 4.17, and Strongly Overvalued above 4.17. The current Forward EV/EBITDA of -0.31 falls within the Historic Trend Line -Fairly Valued range.

-0.33

EV/EBIT

Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current EV/EBIT of -0.33. The 5-year average EV/EBIT is -1.33. The thresholds are as follows: Strongly Undervalued below -7.12, Undervalued between -7.12 and -4.22, Fairly Valued between 1.56 and -4.22, Overvalued between 1.56 and 4.46, and Strongly Overvalued above 4.46. The current Forward EV/EBIT of -0.33 falls within the Historic Trend Line -Fairly Valued range.

126.84

Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current PS of 126.84. The 5-year average PS is 71.50. The thresholds are as follows: Strongly Undervalued below -234.39, Undervalued between -234.39 and -81.44, Fairly Valued between 224.45 and -81.44, Overvalued between 224.45 and 377.40, and Strongly Overvalued above 377.40. The current Forward PS of 126.84 falls within the Historic Trend Line -Fairly Valued range.

-2.15

P/OCF

Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current P/OCF of -2.15. The 5-year average P/OCF is -2.46. The thresholds are as follows: Strongly Undervalued below -12.44, Undervalued between -12.44 and -7.45, Fairly Valued between 2.53 and -7.45, Overvalued between 2.53 and 7.52, and Strongly Overvalued above 7.52. The current Forward P/OCF of -2.15 falls within the Historic Trend Line -Fairly Valued range.

-1.86

P/FCF

Corbus Pharmaceuticals Holdings Inc. (CRBP) has a current P/FCF of -1.86. The 5-year average P/FCF is -2.67. The thresholds are as follows: Strongly Undervalued below -9.64, Undervalued between -9.64 and -6.16, Fairly Valued between 0.82 and -6.16, Overvalued between 0.82 and 4.30, and Strongly Overvalued above 4.30. The current Forward P/FCF of -1.86 falls within the Historic Trend Line -Fairly Valued range.

Corbus Pharmaceuticals Holdings Inc (CRBP) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 6.82 , the current P/B ratio is approximately -81.30% higher. Relative to its 5-year average P/B ratio of 4.91, the current P/B ratio is about -73.98% higher. Corbus Pharmaceuticals Holdings Inc (CRBP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -92.85%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -85.25% , the current FCF yield is about -100.00% lower.

1.27

P/B

Median3y

6.82

Median5y

4.91

-41.09

FCF Yield

Median3y

-92.85

Median5y

-85.25

Competitors Valuation Multiple

The average P/S ratio for CRBP's competitors is 22.18, providing a benchmark for relative valuation. Corbus Pharmaceuticals Holdings Inc Corp (CRBP) exhibits a P/S ratio of 126.84, which is 471.82% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CRBP.O

Corbus Pharmaceuticals Holdings Inc

Achieve Life Sciences Inc

Performance Decomposition

Market capitalization of CRBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CRBP in the past 1 year is driven by Unknown.